Profund Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Profund Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Sell	22,699 -9,212	-29%	-$89.8K	0.01%	794
2026 Q1	$297K	Buy	31,911 +1,060	+3%	+$9.22K	0.01%	753
2025 Q4	$231K	Buy	+30,851	New	+$313K	0.01%	1072
2024 Q4	–	Sell	-18,142	Closed	-$196K	–	1142
2024 Q3	$196K	Buy	18,142 +180	+1%	+$2.99K	0.01%	1057
2024 Q2	$377K	Sell	17,962 -6,484	-27%	-$163K	0.01%	594
2024 Q1	$779K	Buy	24,446 +9,990	+69%	+$255K	0.03%	427
2023 Q4	$293K	Sell	14,456 -6,598	-31%	-$86.8K	0.01%	792
2023 Q3	$268K	Sell	21,054 -7,725	-27%	-$129K	0.01%	722
2023 Q2	$520K	Buy	28,779 +3,700	+15%	+$68.1K	0.03%	500
2023 Q1	$431K	Buy	+25,079	New	+$488K	0.03%	544

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Profund Advisors's FDMT Position: Q2 2026 in Review

Profund Advisors reduced its 4D Molecular Therapeutics (FDMT) stake by 29% in Q2 2026, selling an estimated $89.8K and leaving 22,699 shares worth $302K. The position accounts for 0.01% of the portfolio, ranked #794.

Profund Advisors first reported a position in FDMT in Q1 2023 and has held it in 10 quarters since. The position peaked at $779K in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Profund Advisors held 22,699 shares of 4D Molecular Therapeutics worth $302K as of Q2 2026.
Profund Advisors sold 9,212 4D Molecular Therapeutics shares in Q2 2026, an estimated $89.8K.
4D Molecular Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #794 holding.
Profund Advisors first reported a position in 4D Molecular Therapeutics in Q1 2023 and has held it in 10 quarters since.
Profund Advisors's 4D Molecular Therapeutics position peaked at $779K in Q1 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.